Table 2. Cox regression models1 for the incidence of TIC2 by risk factors.

Variables		Number of Patients	Incidence		HR	95% CI for HR	P-Value
			No	%
			Median (range) for continuous variables
Age (years)			59 (30–80)		1.16	1.03–1.31	0.019
Gender
	Male	52	4	7.7	1.49	0.17–13.4	0.722
	Female	18	1	5.6	1
BMI (kg/m2)			21.4 (13.8–32.5)		0.94	0.69–1.28	0.701
Hypertension
	Yes	18	2	11.1	1.74	0.29–10.5	0.545
	No	52	3	5.8	1
Diabetes
	Yes	8	0	0	N/A		N/A
	No	62	5	8.1
Smoking
	Current/Former	38	0	0	N/A		N/A
	Never	32	5	15.6
Baseline LVEF (%)
	≥55 and ≤60	20	1	5.0	1.60	0.18–14.3	0.677
	≥60	50	4	8.0	1
Baseline serum CRP (mg/L)			13.3 (0–201)		1.00	0.98–1.02	0.799
Total cholesterol (mg/dL)			153.5 (74–343)		1.00	0.99–1.02	0.769
Cycle (number)			9 (1–62)		0.99	0.92–1.08	0.844
Cumulative dose (mg/kg)			56 (8–374)		1.00	0.98–1.02	0.927
Combined cytotoxic chemotherapy
	FP	31	4	12.9	6.74	0.74–61.6	0.091
	SP/XP	39	1	2.6	1

BMI, body mass index; CRP, C-reactive protein; FP, fluorouracil plus cisplatin chemotherapy; HR, hazard ratio; LVEF, left ventricular ejection fraction; SP, TS-1 plus cisplatin chemotherapy; TIC, trastuzumab-induced cardiotoxicity; XP, capecitabine plus cisplatin chemotherapy; ¹trastuzumab treatment group only; N=70; ²TIC was defined as at least one of the following: decreased LVEF ≥10% points to a value of <55%, severe congestive heart failure, or cardiac death.